Modern Chinese Medicine Group (1643) Fundamentals 2026 — Revenue Analysis | SniperIQ
Modern Chinese Medicine Group (1643) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK$576M, trading at HK$0.80 on the HKSE. This SniperIQ fundamentals page covers Modern Chinese Medicine Group's valuation, profitability (net margin -9.2%), revenue (¥141M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Modern Chinese Medicine Group's market cap?
Modern Chinese Medicine Group (1643) has a market capitalization of approximately HK$576M, trading at HK$0.80 on the HKSE. Market cap moves with the live share price.
What is Modern Chinese Medicine Group's P/E ratio?
Modern Chinese Medicine Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Modern Chinese Medicine Group?
Modern Chinese Medicine Group runs a net profit margin of -9.2%, a gross margin of 16.2%, and an operating margin of -11.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Modern Chinese Medicine Group generate?
Modern Chinese Medicine Group reported revenue of ¥141M for fiscal year 2025, with net income of -¥13M and earnings per share (EPS) of -0.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Modern Chinese Medicine Group pay a dividend?
Modern Chinese Medicine Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Modern Chinese Medicine Group financially healthy?
Modern Chinese Medicine Group carries a debt-to-equity ratio of 0.00x and a current ratio of 8.54x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Modern Chinese Medicine Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Modern Chinese Medicine Group (1643) the key facts are: market cap HK$576M, revenue ¥141M, 52-week range 0.485-3.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Modern Chinese Medicine Group's full fundamentals live
Get Modern Chinese Medicine Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.